Company news

Corbus Pharmaceuticals Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

October 15, 2024

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

August 19, 2024

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

August 5, 2024

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

April 23, 2024

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

April 1, 2024

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

March 11, 2024

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

February 27, 2024

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

February 1, 2024

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

January 8, 2024

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

December 17, 2023

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 6, 2023

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

October 16, 2023

Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 7, 2023

Corbus Pharmaceuticals Set to Join Russell Microcap® Index

June 25, 2023

Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 8, 2023

Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update

March 6, 2023

Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA

March 5, 2023

Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)

February 12, 2023

Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 7, 2022

Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors

September 25, 2022

Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 8, 2022

Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates

March 7, 2022

Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

December 6, 2021

Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

November 11, 2021

Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

August 11, 2021

Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

June 23, 2021

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

May 31, 2021

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress

May 24, 2021

Corbus Pharmaceuticals announces adjournment of annual meeting

May 18, 2021

Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates

May 12, 2021

Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)

April 19, 2021

Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

March 29, 2021

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results

March 14, 2021

Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021

March 7, 2021

Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases

January 19, 2021

Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates

November 9, 2020

Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020

November 2, 2020

Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020

October 22, 2020

Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020

October 20, 2020

Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates

October 7, 2020

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

October 5, 2020

Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

September 7, 2020

Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates

August 5, 2020

Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

August 4, 2020

Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors

July 7, 2020

Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

June 21, 2020

Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis

May 31, 2020

Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

May 26, 2020

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 45 decks. Every deck is listed under its year.